Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.

Rossi JF, Moreaux J, Hose D, Requirand G, Rose M, Rouillé V, Nestorov I, Mordenti G, Goldschmidt H, Ythier A, Klein B.

Br J Cancer. 2009 Oct 6;101(7):1051-8. doi: 10.1038/sj.bjc.6605241.

2.

APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.

Moreaux J, Sprynski AC, Dillon SR, Mahtouk K, Jourdan M, Ythier A, Moine P, Robert N, Jourdan E, Rossi JF, Klein B.

Eur J Haematol. 2009 Aug;83(2):119-29. doi: 10.1111/j.1600-0609.2009.01262.x. Epub 2009 May 30.

PMID:
19456850
3.

Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma.

Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, Nestorov I, Devries T, Dillon SR, Hausman D, Novak AJ.

Clin Cancer Res. 2008 Feb 15;14(4):1105-10. doi: 10.1158/1078-0432.CCR-07-4435.

4.
5.

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.

Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, Biollaz J.

J Neuroimmunol. 1999 Sep 1;99(1):131-41.

PMID:
10496186
6.

Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer.

Lou J, Gasche Y, Zheng L, Giroud C, Morel P, Clements J, Ythier A, Grau GE.

Lab Invest. 1999 Aug;79(8):1015-25.

PMID:
10462039
7.

Effects of urinary gonadotrophin preparations on human in-vitro immune function.

Biffoni M, Marcucci I, Ythier A, Eshkol A.

Hum Reprod. 1998 Sep;13(9):2430-4.

PMID:
9806263
8.

Modulation of soluble and membrane-bound TNF-induced phenotypic and functional changes of human brain microvascular endothelial cells by recombinant TNF binding protein I.

Lou J, Ythier A, Burger D, Zheng L, Juillard P, Lucas R, Dayer JM, Grau GE.

J Neuroimmunol. 1997 Jul;77(1):107-15.

PMID:
9209275
9.

The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.

Kruithof EK, Mestries JC, Gascon MP, Ythier A.

Thromb Haemost. 1997 May;77(5):905-10.

PMID:
9184401
10.

The effect of factor Xa/phospholipid infusion on the acute phase response in baboons.

Kruithof EK, Agay D, Mestries JC, Gascon MP, Ythier A.

Thromb Haemost. 1997 Feb;77(2):308-11.

PMID:
9157587
11.

Structural predictions for the ligand-binding region of glycoprotein hormone receptors and the nature of hormone-receptor interactions.

Jiang X, Dreano M, Buckler DR, Cheng S, Ythier A, Wu H, Hendrickson WA, el Tayar N.

Structure. 1995 Dec 15;3(12):1341-53.

12.

Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis.

Porat R, Paddock HN, Schwaitzberg SD, Connolly RJ, Wilkens T, Dasch JR, Gascon MP, Hutchison JS, Ythier A, Wallach D, et al.

Crit Care Med. 1995 Jun;23(6):1080-9.

PMID:
7774220
13.

Determination of haptoglobin expression in IL-6 treated HepG2 cells by ELISA and by RNA hybridization--evaluation of a quantitative method to measure IL-6.

Boe A, Canosi U, Donini S, Mastrangeli R, Ythier A, Crescenzi OS.

J Immunol Methods. 1994 May 16;171(2):157-67.

PMID:
8195587
14.

In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons.

Mestries JC, Kruithof EK, Gascon MP, Herodin F, Agay D, Ythier A.

Eur Cytokine Netw. 1994 May-Jun;5(3):275-81.

PMID:
7948765
15.

Protective effect of natural TNF-binding protein on human TNF-induced toxicity in mice.

Ythier A, Gascon MP, Juillard P, Vesin C, Wallach D, Grau GE.

Cytokine. 1993 Sep;5(5):459-62.

PMID:
8142601
16.

Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxic shock.

Bertini R, Delgado R, Faggioni R, Gascon MP, Ythier A, Ghezzi P.

Eur Cytokine Netw. 1993 Jan-Feb;4(1):39-42.

PMID:
8387827
17.

Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons.

Herodin F, Mestries JC, Janodet D, Martin S, Mathieu J, Gascon MP, Pernin MO, Ythier A.

Blood. 1992 Aug 1;80(3):688-95.

PMID:
1638022
18.

Pharmacokinetics and tissue distribution of human urinary tumor necrosis factor binding protein in mice.

Gascon MP, Porchet HC, Le Cotonnec JY, Ythier A, Wallach D, Piguet PF, Grau GE.

Drug Metab Dispos. 1992 Jul-Aug;20(4):592-5.

PMID:
1356740
19.

Differential effect of gamma-irradiated and heat-treated lymphocytes on T cell activation, and interleukin-2 and interleukin-3 release in the human mixed lymphocyte reaction.

Loertscher R, Abbud-Filho M, Leichtman AB, Ythier AA, Williams JM, Carpenter CB, Strom TB.

Transplantation. 1987 Nov;44(5):673-80.

PMID:
2961113
20.

A unique T-cell receptor complex expressed on human fetal lymphocytes displaying natural-killer-like activity.

Moingeon P, Ythier A, Goubin G, Faure F, Nowill A, Delmon L, Rainaud M, Forestier F, Daffos F, Bohuon C, et al.

Nature. 1986 Oct 16-22;323(6089):638-40.

PMID:
3095661
21.

Allogeneic responses of human fetal (22- to 25-week) peripheral blood lymphocytes: preferential recruitment of cytotoxic effector cells with both CTL activity and NK-like function.

Nowill A, Graziani M, Raynaud M, Delmon L, Ythier A, Moingeon P, Daffos F, Hercend T.

Cell Immunol. 1986 Oct 15;102(2):355-63.

PMID:
3026652
22.

Characterization of antileukemia cells' cytotoxic effector function. Implications for monitoring natural killer responses following allogeneic bone marrow transplantation.

Delmon L, Ythier A, Moingeon P, Nowill A, Bayle C, Pico JL, Hayat M, Ritz J, Hercend T.

Transplantation. 1986 Sep;42(3):252-6.

PMID:
3529526
23.

Natural killer clones derived from fetal (25 wk) blood. Probing the human T cell receptor with WT31 monoclonal antibody.

Nowill A, Moingeon P, Ythier A, Graziani M, Faure F, Delmon L, Rainaut M, Forrestier F, Bohuon C, Hercend T.

J Exp Med. 1986 Jun 1;163(6):1601-6.

24.

Generation of monoclonal antibodies blocking cytotoxic reactions by human NK clones: further characterization of a 40/80-kDa target cell receptor.

Ythier A, Moingeon P, Fabbi M, Delmon L, Nowill A, Troelen F, Bohuon C, Hercend T.

Cell Immunol. 1986 Apr 15;99(1):150-9.

PMID:
2428527
25.

Short-term culture of acute myeloid leukemia blasts: analysis of acquired susceptibility to activated natural killer cells.

Moingeon P, Ythier A, Nowill A, Delmon L, Bayle C, Pico JL, Bohuon C, Hercend T.

Blood. 1986 Mar;67(3):777-83.

PMID:
3456248
26.

Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation.

Hercend T, Takvorian T, Nowill A, Tantravahi R, Moingeon P, Anderson KC, Murray C, Bohuon C, Ythier A, Ritz J.

Blood. 1986 Mar;67(3):722-8.

PMID:
3081066
27.

Stages of T cell activation: continued antigen dependence of IL 2-producing cells after IL 2 receptor expression.

Miller RA, Rozans MK, Ythier AA, Strom TB.

J Immunol. 1986 Feb 1;136(3):977-83.

PMID:
2416843
28.

Proliferative responses of circulating human NK cells: delineation of a unique pathway involving both direct and helper signals.

Ythier A, Delmon L, Reinherz E, Nowill A, Moingeon P, Mishal Z, Bohuon C, Hercend T.

Eur J Immunol. 1985 Dec;15(12):1209-15.

PMID:
3936722
29.

The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection.

Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Koltun WA, Schoen FJ, Ythier A, Strom TB.

Transplantation. 1985 Dec;40(6):719-22.

PMID:
3934807
30.

Interleukin 2-dependent release of interleukin 3 activity by T4+ human T-cell clones.

Ythier AA, Abbud-Filho M, Williams JM, Loertscher R, Schuster MW, Nowill A, Hansen JA, Maltezos D, Strom TB.

Proc Natl Acad Sci U S A. 1985 Oct;82(20):7020-4.

31.

Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice.

Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB.

J Exp Med. 1985 Jul 1;162(1):358-62.

32.

A target structure for a series of human cloned natural killer cell lines is recognized by both anti-TNKtar and 4F2 monoclonal antibodies.

Moingeon P, Nowill A, Courtois G, Azzarone B, Motte P, Ythier A, Bohuon C, Hercend T.

J Immunol. 1985 May;134(5):2930-4.

PMID:
3980986
33.

The early (18-hr) human mixed lymphocyte reaction: identification and isolation of activated T-cell clones.

Ythier AA, Williams JM, Shapiro HM, Kelley VE, Strom TB.

Cell Immunol. 1985 Mar;91(1):215-26.

PMID:
2982504
34.

[Interleukins: factors of intercellular communication].

Ythier A.

Ann Biol Clin (Paris). 1985;43(5):722-4. French.

PMID:
3937465
35.

Improved culture conditions for quantitative evaluation of interleukin 2 production by frozen human lymphocytes.

Harel-Bellan A, Marchiol C, Kaplan C, Muller JY, Chouaib S, Ythier A, Nowill A, Fradelizi D.

J Immunol Methods. 1983 Nov 11;64(1-2):61-9.

PMID:
6605999
36.

HLA-AB and -DR types in patients with infectious mononucleosis (IM).

Ythier A, Moreau JF, Peyrat MA, Bignon JD, Soulillou JP.

Tissue Antigens. 1983 Apr;21(4):329-32.

PMID:
6574620
37.

Decrease in natural killer cell activity in kidney allograft recipients.

Moreau JF, Soulillou JP, Ythier A, Hegaret A, Fauconnier B.

Ann Immunol (Paris). 1983 Mar-Apr;134C(2):191-205.

PMID:
6191619
38.

Plasma exchange in early kidney graft rejection associated with anti-donor antibodies.

Soulillou JP, Guyot C, Guimbretiere J, Girard M, Ythier A, Bignon JD, Hourmant M, Guenel J.

Nephron. 1983;35(3):158-62.

PMID:
6355877
39.

Natural killer activity in kidney allograft recipients.

Moreau JF, Ythier A, Soulillou JP.

Transplant Proc. 1981 Sep;13(3):1610-3. No abstract available.

PMID:
7029823
40.

[Inhibition of NK activity by oses: effect of interleukin 2 (author's transl)].

Vie H, Ythier A, Moreau JF, Peyrat MA, Soulillou JP.

Ann Immunol (Paris). 1981 May-Jun;132C(3):327-37. French.

PMID:
6174070

Supplemental Content

Loading ...
Support Center